Just caught up on some interesting biotech news that could matter for the rare disease space. Cogent Biosciences got FDA Breakthrough Therapy Designation for their Bezuclastinib combo with Sunitinib targeting GIST patients who've already failed Imatinib treatment.

What caught my attention is the PEAK trial data backing this - they're showing a 50% reduction in disease progression or death risk compared to Sunitinib alone. Median progression-free survival jumped from 9.2 months up to 16.5 months. That's a meaningful improvement in a disease area that honestly hasn't seen much innovation in over 20 years.

For context, GIST is driven by KIT mutations, and the resistance problem is real - patients who progress on Imatinib typically hit a wall with existing options. This combo specifically targets KIT exon 17 mutations that drive that resistance, which is why the FDA fast-tracked it.

The safety profile looks clean too. No new red flags beyond what they already knew from Sunitinib. FDA already agreed to review the NDA under their Real-Time Oncology Review program, so Cogent can submit pieces of the application as they're ready.

Looking ahead, they're targeting NDA submission for GIST in April 2026 (which is basically now), and they're planning a Phase 2 trial mid-2026 for first-line GIST patients with exon 9 mutations. They've also got Bezuclastinib in systemic mastocytosis development, with multiple NDA submissions expected across their programs in the first half of 2026.

Cogent's sitting on roughly 900 million in cash, so they're well-funded to push through launches into 2028. Stock has been volatile - traded anywhere from $3.72 to $43.73 over the past year. Last I saw it was around $37.86, up a few percent. Interesting story if you follow precision oncology or rare disease therapeutics.